Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market

   Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass
                  Expectations For $3.5 Billion ADHD Market

PR Newswire

CORAL SPRINGS, Florida, February 4, 2014

CORAL SPRINGS, Florida, February 4, 2014 /PRNewswire/ --

Market Briefing for leading pharma advancers along with clinical data reveals
biotech company is on the verge of fulfilling glaring market need: Amarantus
Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE),
IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ:
ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc.

Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company
focused on the discovery and development of novel diagnostics and therapeutics
related to endoplasmic reticulum stress, cell cycle dysregulation,
neurodegeneration and apoptosis, today announced positive clinical data for
Eltoprazine in a Phase 2a clinical study Adult Attention Deficit Hyperactivity
Disorder. The results from the study demonstrated statistically significant
improvements of both doses of 5mg and 10mg vs. placebo in a range of ADHD
clinical measures."Following a thorough statistical review of the data
announced by Psychogenics in 2008 by an independent clinical CRO retained for
due diligence purposes, an updated study report was submitted in the
Investigator's Brochure in 2010 that was better than originally reported,"
said David A. Lowe, PhD member of the Amarantus Board of Directors. "There is
a significant need for non-stimulant ADHD treatments in the marketplace,
especially in light of recent regulatory oversight of abuse of currently
approved treatments. We believe Eltoprazine may fill this market need." The
ADHD market is valued at over $3.5 billion dollars, with approximately 35
million prescriptions written annually. 

To read the full press release and get all the data results, please click

Eltoprazine is a 5HT1a/1b partial agonist small molecule drug candidate has a
well-established safety profile, having been dosed in over 700 patients to
date. The study entitled "The Effects of Eltoprazine on Symptoms of Attention
Deficit Hyperactivity Disorder (ADHD) in Adults: A Double-Blind, Multiple
Dose, Crossover, Safety and Preliminary Efficacy Trial" enrolled 47 patients
(48 enrollees were planned), with 36 patients completing the study. The study
was conducted at 4 centers in the United States, including Duke University
Medical Center, Riley Hospital for Children, NeuroScience, Inc. and UCI Child
Development Center.

Pfizer Inc. (NYSE: PFE) has announced that the randomized Phase 2 trial
[PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a
statistically significant and clinically meaningful improvement in
progression-free survival (PFS) for the combination of palbociclib and
letrozole compared with letrozole alone in post-menopausal women with estrogen
receptor positive (ER+), human epidermal growth factor receptor 2 negative
(HER2-) locally advanced or newly diagnosed metastatic breast cancer. "We are
delighted with the final data, which suggest the potential for palbociclib to
transform the standard of care for post-menopausal women with ER+ and HER2-
advanced breast cancer. This is encouraging information for these women, who
represent approximately 60 percent of the advanced breast cancer population,"
said Dr. Mace Rothenberg, senior vice president of Clinical Development and
Medical Affairs and chief medical officer for Pfizer Oncology. "We will
discuss these results with the FDA and other regulatory authorities to
determine next steps, with the goal of bringing a much-needed new medicine to

IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) a pharmaceutical
company specializing in the research, development and manufacture of novel and
generic controlled-release and targeted-release oral solid dosage drugs,
recently announced the receipt of approximately $3.1 million as its first
payment relating to commercial sales of dexmethylphenidate hydrochloride
extended-release capsules by its licensee Par Pharmaceutical, Inc. ("Par").
This represents the Company's share of profits for the 15 and 30 mg strengths
of the drug product for the period commencing with the first commercial sales
of those strengths on November 19, 2013 and ending December 31, 2013 under its
License and Commercialization Agreement with Par. Future profit-share payments
are expected on a quarterly basis, although the amounts of any such payments
cannot now be determined and may vary significantly from time-to-time. All
dollar amounts referenced herein are in United States dollars unless otherwise

Alcobra Ltd. (NASDAQ: ADHD) an emerging biopharmaceutical company primarily
focused on the development and commercialization of its proprietary drug
candidate, MG01CI (Metadoxine extended-release), to treat cognitive
dysfunctions, such as ADHD and Fragile X Syndrome, recently announced that
Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide
a corporate overview at the BIO CEO & Investor Conference, being held at the
Waldorf Astoria Hotel in New York City on February 10-11, 2014. The Alcobra
presentation is on Monday, February 10 at 3:30pm Eastern Time. 

Horizon Pharma, Inc. (NASDAQ: HZNP) has announced that on January 9, 2014 the
Compensation Committee of its Board of Directors approved the grant of
inducement stock options to purchase an aggregate of 363,900 shares of common
stock to 93 new employees. Each stock option has an exercise price per share
equal to $8.59, the fair market value on the grant date, and vests over four
years, with 25% of the shares vesting on the one-year anniversary of the
applicable vesting commencement date and 1/48 of the shares vesting monthly
thereafter, subject to the new employee's continued service relationship with
the Company. Each stock option also has a ten-year term and is subject to the
terms and conditions of the Company's 2011 Equity Incentive Plan and the stock
option agreement pursuant to which the option was granted.

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)recently announced that the U.S.
Food and Drug Administration (FDA) has approved HETLIOZ™ (tasimelteon) 20mg
capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
HETLIOZ™ is the first FDA approved medication for Non-24. Non-24 was first
described more than 60 years ago, and is a chronic, circadian rhythm disorder
resulting from the misalignment of the endogenous master body clock to the
24-hour day, disrupting the sleep-wake cycle. Non-24 affects the majority of
totally blind individuals and it is estimated that approximately 80,000
Americans have the disorder. "The FDA approval of HETLIOZ™ would not have been
accomplished without the heroic efforts of blind patients and their
advocates," said Mihael H. Polymeropoulos, M.D., Vanda's President and Chief
Executive Officer. "We are committed to providing much needed support to
patients with Non-24 and facilitating access to this new therapeutic option."

FinancialNewsMedia.comis leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visithttp://www.financialnewsmedia.comfor more
details. Get an edge on the market with ourPremium News Alertsthat are FREE
for a limited time at Follow us on

FN Media Group LLC (FNMG) owns and operates (FNM) which
is a third party publisher that disseminates electronic information through
multiple online media channels. FNMG's intended purposes are to deliver market
updates and news alerts issued from private and publicly trading companies as
well as providing coverage and increased awareness for companies that issue
press to the public via online newswires. FNMG and its affiliated companies
are a news dissemination and financial marketing solutions provider and are
NOT a registered broker/dealer/analyst/adviser, holds no investment licenses
and may NOT sell, offer to sell or offer to buy any security. FNMG's market
updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this release
is intended to be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed financial
professional before considering any level of investing in stocks. The
companies that are discussed in this release may or may not have approved the
statements made in this release. Information in this release is derived from a
variety of sources that may or may not include the referenced company's
publicly disseminated information. The accuracy or completeness of the
information is not warranted and is only as reliable as the sources from which
it was obtained. While this information is believed to be reliable, such
reliability cannot be guaranteed. FNMG disclaims any and all liability as to
the completeness or accuracy of the information contained and any omissions of
material fact in this release. This release may contain technical inaccuracies
or typographical errors. It is strongly recommended that any purchase or sale
decision be discussed with a financial adviser, or a broker-dealer, or a
member of any financial regulatory bodies. Investment in the securities of the
companies discussed in this release is highly speculative and carries a high
degree of risk. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. This release is not without bias,
and is considered a conflict of interest if compensation has been received by
FNMG for its dissemination. To comply with Section 17(b) of the Securities Act
of 1933, FNMG shall always disclose any compensation it has received, or
expects to receive in the future, for the dissemination of the information
found herein on behalf of one or more of the companies mentioned in this
release. For current services performed FNMG has been compensated one thousand
five hundred dollars for Amarantus Bioscience Holdings, Inc news coverage by
the Company.

FNMG HOLDS NO SHARES OF Amarantus Bioscience Holdings, Inc.

This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611

Press spacebar to pause and continue. Press esc to stop.